BeOne Medicines (BEIGF) Capital Expenditures (2015 - 2026)

BeOne Medicines (BEIGF) has reported Capital Expenditures for 12 consecutive years, with $25.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 37.81% year-over-year to $25.0 million in Q2 2026; TTM through Jun 2026 was $153.9 million, a 52.85% decrease from a year earlier, with the FY2025 full-year figure at $185.8 million, down 62.28% from the prior year.
• Capital Expenditures was $25.0 million for Q2 2026 at BeOne Medicines, down from $43.2 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $157.9 million in Q3 2023 and troughed at $25.0 million in Q2 2026.
• A 5-year average of $90.8 million and a median of $100.6 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 271.64% in 2023 and sank 64.02% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $121.4 million in 2022, then climbed by 29.34% to $157.0 million in 2023, then slumped by 41.08% to $92.5 million in 2024, then slumped by 59.43% to $37.5 million in 2025, then plunged by 33.33% to $25.0 million in 2026.
• The last three Capital Expenditures figures came in at $25.0 million (Q2 2026), $43.2 million (Q1 2026), and $37.5 million (Q4 2025), per Business Quant data.